Page 1

Animalcare Group plc Interim Results for the six months ended 30 June 2021 28 September 2021. Animalcare Group plc ( " the Company " or " Group " ) ( AIM : ANCR ) , the international animal health business , announces its unaudited interim results for the six months ended 30 June 2021 . Animalcare has delivered a very strong first half with double - digit revenue and profit growth and a further strengthening of our financial position . Driven by the continuation of favourable trading conditions into the second half , the Board expects that underlying EBITDA and underlying basic EPS for the full year will be ahead of current market expectations . Financial Highlights • Revenue increased 13.3 % ( 14.2 % at CER ) to £ 39.1m compared to prior period ( H1 2020 : £ 34.5m ) with sales growth particularly strong within Companion Animals • • • • Gross profit margin increased 2.6 % to 54.6 % compared to prior period ( H1 2020 : 52.0 % ) , benefiting from a continued focus on brands with higher growth and margin potential Underlying * EBITDA up 28.3 % on the prior period to £ 8.5m , largely reflecting strong revenue growth coupled with higher margin sales mix Underlying basic EPS increased by 35.6 % to 8.0 pence ( H1 2020 : 5.9 pence ) Statutory profit before tax , incorporating non - underlying items was £ 0.8m ( H1 2020 : £ 0.8m ) , with reported basic EPS at 0.5 pence ( H1 2020 : 0.8 pence ) Net debt further reduced by £ 3.5m to £ 10.1m as of 30 June 2021 supported by continued strong cash conversion . Net debt to underlying EBITDA leverage ratio reduced to approximately 0.7 times • Board declares interim dividend of 2.0 pence per share * The Group presents a number of non - GAAP Alternative Performance Measures ( APMs ) which exclude non - underlying items as set out in note 3. EBITDA is defined as underlying earnings before interest , tax , depreciation and amortisation . Strategic and Operational Highlights Pipeline · Following approval by EU and UK authorities , Daxocox launch activities commenced at the end of the first half while the STEM dental range of products remains on track to complete manufacturing transfer and launch in late Q4 The Group plans to increase investment in the development pipeline versus the prior year and further still into 2022 Business development The Group continues to pursue business development opportunities that will further Animalcare's strategic priorities : strengthening and building the pipeline ; enhancing earnings through sustainable commercial deals ; and scaling up and extending the geographic footprint Operational Highlights • New organisation structure and streamlined leadership team implemented to support delivery of growth strategy Animalcare's Chief Executive Officer , Jenny Winter , commented : " We delivered a very strong set of results for the first six months supported by growing demand in our Companion Animals segment . Increased revenues and profit fed through to improvements in our balance sheet , further strengthening the Group's capacity to pursue value - creating opportunities that align with our growth strategy . Encouraged by the trading momentum carried into the third quarter we are confident that profit performance will be ahead of current market expectations for the full year .